NanoViricides Inc. (NNVC)

[NNVClover]

It's actually a great R/R. $150m company with little cash resources and no clinical candidates nominated for the normal battery of IND-enabling studies. That means it will be $200m fully diluted. There are no companies remotely near that valuation. Given the technology has been described before I doubt there is significant IP. There are substantial clinical hurdles and the delays in reaching even a lead nomination stage are suggestive of formulation/PK problems. The management team is vastly underqualified and no investors have stepped up to the table to acquire any position in the company, even a small one. I see the stock trading at book value with time. Many healthcare stocks do - this one is not noteworthy enough to warrant a premium.